- Company
- Donepezil ↑8%, memantine 10%↑…replaces choline alfoscerat
- by Kim, Jin-Gu Aug 7, 2025 06:10am
- Sales of donepezil, memantine, and nicergoline-based dementia treatments, which have emerged as alternatives to choline alfoscerate formulations, are growing. In the first half of this year, donepezil’s sales recorded KRW 162.6 billion, an 8% increase from the previous year. Sales of memantine-based formulation increased by 10% year-on
- Company
- Yuhan’s Leclaza to receive ₩100B in milestone payment
- by Chon, Seung-Hyun Aug 7, 2025 06:06am
- With Yuhan Corp’s new anticancer drug Leclaza approved in China, the company announced that it will receive KRW 63 billion in technology fees. Added to the technology fees secured at the end of last year for the drug’s approval in Europe, over KRW 100 billion in additional milestone payments are expected to be paid to the company. As a result,
- Policy
- Gov’t sets criteria for drug shortage prevention
- by Lee, Hye-Kyung Aug 7, 2025 06:06am
- The government will improve the criteria to raise the prices of drugs essential for patient treatment. Specifically, it will establish detailed evaluation criteria for price adjustment requests submitted by pharmaceutical companies that deem the current insurance price ceiling unreasonable. Prime Minister Min-seok Kim chaired the 7th Bioh
- Policy
- H1 Pharma exports amounted to $5.38B
- by Lee, Hye-Kyung Aug 7, 2025 06:05am
- In the first half of this year, healthcare industry exports increased by 13.2% compared to the same period last year, reaching $13.79 billion, an all-time high for a half-year period. By sector, exports were led by cosmetics at $5.51 billion (+14.9%), pharmaceuticals at $5.38 billion (+20.5%), and medical devices at $2.91 billion (△0.6%).
- Company
- 'Brintellix', stable position in antidepressant drugs mkt
- by Eo, Yun-Ho Aug 7, 2025 06:05am
- 'Brintellix' has established a stable presence in the antidepressant drugs market over the past 10 years. Its presence has not been disturbed by issues such as generic entries. According to industry sources, Lundbeck Korea's Brintellix (vortioxetine) has been growing in the market for antidepressant drugs for the past 10 years. In Q1 2012
- Company
- COVID-19 vaccines transitioned to NIP
- by Whang, byung-woo Aug 6, 2025 06:10am
- COVID-19 vaccines, which were previously contracted through a pre-purchase model with pharmaceutical companies, will transition to the National Immunization Program (NIP) system. The Korea Disease Control and Prevention Agency (KDCA) announced on August 5 that it has signed a procurement contract for the supply of vaccines for the 2025-202
- Company
- Imfinzi wins nod as pre- and post-operative adjuvant therapy
- by Whang, byung-woo Aug 6, 2025 06:10am
- AstraZeneca announced on August 4 that it has received approval for its Imfinzi (durvalumab) as pre- and post-operative adjuvant therapy for patients with muscle-invasive bladder cancer from the Ministry of Food and Drug Safety on July 30. With this approval, Imfinzi has become the first and only immunotherapy in Korea to be approved for
- Company
- US drug price 3.9 times higher than in Korea
- by Kim, Jin-Gu Aug 6, 2025 06:09am
- With the US government pushing forward the introduction of a Most Favored Nation (MFN) policy to lower drug prices, an analysis has revealed that US drug prices are 3.9 times higher than those in South Korea. The Korea Biotechnology Industry Organization cited an analysis by the US public policy research institute Rand Corporation on the
- Opinion
- [Reporter's View] Can NA resolve the drug shortage issue?
- by Kim, Jin-Gu Aug 6, 2025 06:09am
- Whether the four bills presented for amendments to the Pharmaceutical Affairs Act aimed at resolving the shortage of medicines will be discussed at the National Assembly's Health and Welfare Committee in August is gaining attention. The amendments to the Pharmaceutical Affairs Act were proposed by Rep. Jeong-ae Han, Rep. Yoon Kim, and Rep
- Company
- GIST drug Qinlock receives orphan drug designation in KOR
- by Eo, Yun-Ho Aug 6, 2025 06:09am
- The GIST treatment Qinlock has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety announced the news through a public notice on the 4th. Ono Pharmaceutical's gastrointestinal stromal tumor (GIST) treatment Qinlock (ripreitinib) had previously been designated as a Global Innovative Products on Fast Track (GIFT
